Pfizer gets CRL on Epogen biosimilar from FDA

05:31 EDT 23 Jun 2017 | Pharmaceutical Business Review

The United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Pfizer in connection with its biosimilar candidate to Amgen’s anemia drug Epogen (epoetin alfa).

Original Article: Pfizer gets CRL on Epogen biosimilar from FDA


More From BioPortfolio on "Pfizer gets CRL on Epogen biosimilar from FDA"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...